Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

Eli Lilly's Alzheimer's drug, donanemab (Kisqali), just got a thumbs-up from the European Medicines Agency's (EMA) expert ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Thursday’s episode of Mad Money, host Jim Cramer turned his focus to large-cap stocks that surged by $10 or more in a single day.

While Leerink still expects Zoetis to post revenue and earnings growth, it sees the pace decelerating as rivals like Elanco and Merck (NSE: PROR) gain share. The firm forecasts Zoetis EPS growth to ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.